PALO ALTO, Calif. / Nov 03, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences:
Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping every person live a life free from cancer. Founded in 2012, Guardant is transforming cancer care by providing critical insights into what drives the disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve patient outcomes across all stages of cancer, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn and X (Twitter).
| Last Trade: | US$32.10 |
| Daily Change: | 1.54 5.04 |
| Daily Volume: | 185,783 |
| Market Cap: | US$3.970B |
December 18, 2024 November 06, 2024 October 28, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
